Hub : Traits :

Medication for cholesterol

23 significantly associated models · 19 unique genes.

Significant Loci

#	chr	p0	p1	# assoc genes	# joint genes	best TWAS P	best SNP P	cond SNP P	% var exp	joint genes
1	1	109605305	110183021	1	1	1.9e-07	3.8e-07	6.1e-01	99	SORT1
2	1	112761639	113496790	2	1	7.2e-10	1.4e-09	5.1e-04	67	RHOC
3	2	27467598	27949052	1	1	1.2e-07	2.2e-07	1.0e+00	100	FNDC4
4	2	48517552	49073574	1	1	2.1e-07	1.1e-06	8.8e-01	100	STON1
5	3	10617048	12293966	1	1	2.1e-07	5.3e-08	5.8e-02	88	ATG7
6	4	103091730	104503936	1	1	2.0e-07	1.5e-06	7.8e-01	100	CISD2
7	6	160071844	161571560	1	1	6.7e-08	8.8e-08	3.9e-02	85	SLC22A3
8	7	26969253	27468350	1	1	5.1e-09	3.7e-08	1.4e-01	93	HOXA10
9	7	129917130	131315092	1	1	2.4e-07	5.2e-08	5.8e-03	74	RP11-138A9.1
10	11	1242690	2640824	1	1	2.7e-08	6.6e-09	2.7e-02	86	TNNT3
11	11	99859184	101559718	2	1	7.1e-08	1.9e-07	6.3e-01	99	TMEM133
12	12	111154626	112582540	1	1	1.5e-07	2.0e-11	1.4e-05	58	SH2B3
13	16	3969463	5441125	2	2	4.8e-09	6.3e-08	3.2e-01	97	MGRN1 NUDT16L1
14	16	89281093	90172696	1	1	2.9e-07	8.0e-06	1.3e-02	69	MC1R
15	19	48918157	49452462	2	1	1.5e-09	4.3e-07	4.9e-01	98	NTN5

Pleiotropic Associations

Trait	chisq ratio	# genes⁺	# genes⁺⁺	% genes⁺⁺	corr	corr P	genes
Hair Pigment	57.83	6	2	4.4	-0.26	6.2e-01	ATG7 FNDC4 MC1R RP11-138A9.1 SH2B3 TMEM133
Tanning	32.81	4	2	4.4	0.28	7.2e-01	FNDC4 MC1R SH2B3 TMEM133
LDL Cholesterol	32.80	4	1	2.2	-0.67	3.3e-01	FNDC4 NTN5 SH2B3 SORT1
Triglycerides	25.08	2	1	2.2	0.00	1.0e+00	FNDC4 NTN5
High cholesterol (Self-reported)	23.51	5	5	11.1	-0.92	2.9e-02	FNDC4 NTN5 SLC22A3 SORT1 TMEM133
Medication: Blood pressure	18.71	14	9	20.0	-0.98	5.2e-10	ATG7 CISD2 HOXA10 MC1R MGRN1 NTN5 NUDT16L1 RHOC RP11-138A9.1 SH2B3 SLC22A3 STON1 TMEM133 TNNT3
Systolic Blood Pressure	16.79	13	10	22.2	-0.90	2.6e-05	ATG7 FNDC4 HOXA10 MC1R MGRN1 NTN5 NUDT16L1 RHOC RP11-138A9.1 SH2B3 SLC22A3 TMEM133 TNNT3
Cardiovascular Disease	16.34	14	10	22.2	-0.94	4.2e-07	ATG7 CISD2 FNDC4 HOXA10 MGRN1 NTN5 NUDT16L1 RHOC RP11-138A9.1 SH2B3 SLC22A3 SORT1 TMEM133 TNNT3
Medication: Cholesterol lowering	15.37	5	4	8.9	-0.91	3.4e-02	FNDC4 NTN5 SLC22A3 SORT1 TMEM133
Cholesterol lowering medication	15.33	8	4	8.9	-0.91	1.7e-03	FNDC4 MGRN1 NTN5 NUDT16L1 RP11-138A9.1 SLC22A3 SORT1 STON1
Vascular/heart problems diagnosed by doctor	15.17	14	10	22.2	0.94	6.0e-07	ATG7 CISD2 HOXA10 MC1R MGRN1 NTN5 NUDT16L1 RHOC RP11-138A9.1 SH2B3 SLC22A3 STON1 TMEM133 TNNT3
High blood pressure	15.16	12	9	20.0	-0.95	1.6e-06	ATG7 CISD2 HOXA10 MC1R MGRN1 NTN5 NUDT16L1 RHOC RP11-138A9.1 SH2B3 TMEM133 TNNT3
Hypertension (Self-reported)	15.14	14	10	22.2	-0.94	5.6e-07	ATG7 CISD2 HOXA10 MC1R MGRN1 NTN5 NUDT16L1 RHOC RP11-138A9.1 SH2B3 SLC22A3 STON1 TMEM133 TNNT3
Medication: Atorvastatin	12.82	4	2	4.4	-0.98	2.3e-02	FNDC4 NTN5 SLC22A3 SORT1
Medication: Simvastatin	12.72	6	3	6.7	-0.89	1.9e-02	FNDC4 NTN5 RP11-138A9.1 SLC22A3 SORT1 TMEM133
Blood Eosinophil Count	11.66	2	2	4.4	0.00	1.0e+00	RP11-138A9.1 SH2B3
Systolic blood pressure, automated reading	11.60	10	8	17.8	-0.92	1.6e-04	ATG7 HOXA10 MC1R MGRN1 NTN5 NUDT16L1 RHOC SH2B3 TMEM133 TNNT3
Medication: Bendroflumethiazide	11.02	9	5	11.1	-0.99	3.0e-07	ATG7 CISD2 HOXA10 MGRN1 NTN5 RHOC SH2B3 TMEM133 TNNT3
Diastolic blood pressure, automated reading	10.72	10	3	6.7	-0.86	1.4e-03	CISD2 HOXA10 MGRN1 NTN5 NUDT16L1 RHOC RP11-138A9.1 SH2B3 TMEM133 TNNT3
Medication for cholesterol, blood pressure or diabetes	10.01	7	3	6.7	0.96	6.8e-04	CISD2 FNDC4 NTN5 RHOC SH2B3 SORT1 TMEM133
Medication: Blood pressure	9.75	8	4	8.9	-0.95	3.9e-04	ATG7 CISD2 HOXA10 MGRN1 RHOC SH2B3 TMEM133 TNNT3
Medication: Amlodipine	9.23	6	3	6.7	-0.98	9.2e-04	HOXA10 MC1R MGRN1 RHOC TMEM133 TNNT3
Number of treatments/medications taken	8.68	9	4	8.9	-0.97	9.8e-06	CISD2 FNDC4 MGRN1 NTN5 NUDT16L1 RHOC SH2B3 SORT1 TMEM133
Blood White Count	8.54	7	4	8.9	-0.71	7.1e-02	FNDC4 MC1R MGRN1 NUDT16L1 RP11-138A9.1 SH2B3 TMEM133
Hypothyroidism (self reported)	8.52	3	1	2.2	0.00	1.0e+00	MC1R NTN5 SH2B3
Number of self-reported non-cancer illnesses	7.85	7	3	6.7	-0.98	1.6e-04	CISD2 FNDC4 MGRN1 NTN5 NUDT16L1 SH2B3 TMEM133
Medication: Atenolol	7.63	6	1	2.2	-0.98	8.6e-04	HOXA10 RHOC RP11-138A9.1 SH2B3 TMEM133 TNNT3
Gout (self-reported)	7.18	2	1	2.2	0.00	1.0e+00	FNDC4 SH2B3
Hypothyroidism/myxoedema (self-reported)	7.13	3	1	2.2	0.00	1.0e+00	MC1R NTN5 SH2B3
Medication: Ramipril	7.09	7	1	2.2	-0.97	3.2e-04	CISD2 HOXA10 MGRN1 RHOC SH2B3 SLC22A3 TMEM133
Medication: Levothyroxine sodium	7.01	2	1	2.2	0.00	1.0e+00	NTN5 SH2B3
Alcohol intake frequency.	6.93	3	2	4.4	0.00	1.0e+00	CISD2 FNDC4 NTN5
Fasting Glucose	6.92	2	1	2.2	0.00	1.0e+00	CISD2 FNDC4
Medication: Aspirin	6.65	3	2	4.4	0.00	1.0e+00	SH2B3 SLC22A3 SORT1
Angina (self-reported)	6.52	3	2	4.4	0.00	1.0e+00	SLC22A3 SORT1 TMEM133
Medication: Aspirin	6.44	4	2	4.4	-0.98	1.7e-02	CISD2 SH2B3 SLC22A3 SORT1
Medication: Allopurinol	6.38	2	1	2.2	0.00	1.0e+00	FNDC4 SH2B3
Illnesses of father: Heart disease	6.38	4	2	4.4	-0.96	3.9e-02	FNDC4 SH2B3 SLC22A3 SORT1
Angina	6.29	3	2	4.4	0.00	1.0e+00	SLC22A3 SORT1 TMEM133
Blood Platelet Count	5.88	8	6	13.3	-0.67	7.1e-02	FNDC4 MGRN1 NTN5 NUDT16L1 RHOC SH2B3 SLC22A3 STON1
High blood pressure (siblings)	5.81	6	0	0.0	-0.98	3.8e-04	FNDC4 MGRN1 RHOC SH2B3 TMEM133 TNNT3
Medication: Lisinopril	5.18	4	0	0.0	-0.99	1.2e-02	NTN5 RHOC SH2B3 TMEM133
High blood pressure (mother)	5.03	5	0	0.0	-0.99	5.2e-04	HOXA10 RHOC SH2B3 TMEM133 TNNT3
Heart attack	4.94	3	2	4.4	0.00	1.0e+00	SH2B3 SLC22A3 SORT1
Heart attack/myocardial infarction (self-reported)	4.93	3	2	4.4	0.00	1.0e+00	SH2B3 SLC22A3 SORT1
Illnesses of siblings	4.50	4	0	0.0	0.98	2.0e-02	CISD2 RHOC SH2B3 TMEM133
Diabetes diagnosed by doctor	4.49	5	1	2.2	-0.29	6.3e-01	CISD2 FNDC4 RP11-138A9.1 SH2B3 SLC22A3
Relative age of first facial hair	4.36	3	3	6.7	0.00	1.0e+00	ATG7 FNDC4 MC1R
Illnesses of mother	4.32	4	0	0.0	1.00	4.5e-03	HOXA10 NTN5 SH2B3 TMEM133
Impedance of arm (left)	4.31	8	2	4.4	0.07	8.6e-01	ATG7 CISD2 FNDC4 HOXA10 MC1R RP11-138A9.1 SH2B3 TNNT3
Pulse rate, automated reading	4.25	4	1	2.2	-0.82	1.8e-01	FNDC4 MGRN1 NUDT16L1 SORT1
Trunk fat-free mass	4.24	9	2	4.4	0.73	2.5e-02	FNDC4 MC1R MGRN1 NTN5 NUDT16L1 SH2B3 SLC22A3 SORT1 TMEM133
Trunk predicted mass	4.24	9	2	4.4	0.73	2.5e-02	FNDC4 MC1R MGRN1 NTN5 NUDT16L1 SH2B3 SLC22A3 SORT1 TMEM133
Type 2 Diabetes (T2D) (2018)	4.18	4	1	2.2	-0.23	7.7e-01	FNDC4 RP11-138A9.1 SH2B3 SLC22A3
Birth weight of first child	3.99	2	1	2.2	0.00	1.0e+00	ATG7 SH2B3
Arm predicted mass (left)	3.92	8	2	4.4	0.76	3.0e-02	CISD2 FNDC4 NTN5 NUDT16L1 SH2B3 SLC22A3 SORT1 TMEM133
Impedance of arm (right)	3.91	8	2	4.4	-0.09	8.4e-01	ATG7 CISD2 FNDC4 HOXA10 NTN5 RP11-138A9.1 SH2B3 TNNT3
Arm predicted mass (right)	3.91	7	2	4.4	0.85	1.6e-02	FNDC4 NTN5 NUDT16L1 SH2B3 SLC22A3 SORT1 TMEM133
Arm fat-free mass (right)	3.90	8	2	4.4	0.76	2.9e-02	CISD2 FNDC4 NTN5 NUDT16L1 SH2B3 SLC22A3 SORT1 TMEM133
Whole body water mass	3.88	8	2	4.4	0.86	5.6e-03	FNDC4 MGRN1 NTN5 NUDT16L1 SH2B3 SLC22A3 SORT1 TMEM133
Arm fat-free mass (left)	3.87	7	2	4.4	0.78	4.0e-02	CISD2 FNDC4 NTN5 NUDT16L1 SH2B3 SLC22A3 SORT1
Whole body fat-free mass	3.83	7	2	4.4	0.86	1.2e-02	FNDC4 NTN5 NUDT16L1 SH2B3 SLC22A3 SORT1 TMEM133
Impedance of whole body	3.71	7	3	6.7	0.01	9.8e-01	ATG7 CISD2 FNDC4 MC1R RHOC TMEM133 TNNT3
Heart disease (mother)	3.60	1	1	2.2	0.00	1.0e+00	SLC22A3
Illnesses of father: High blood pressure	3.59	2	0	0.0	0.00	1.0e+00	SH2B3 TMEM133
Alcohol intake versus 10 years previously	3.56	2	1	2.2	0.00	1.0e+00	FNDC4 NTN5
Basal metabolic rate	3.49	7	2	4.4	0.87	1.0e-02	FNDC4 NTN5 NUDT16L1 SH2B3 SLC22A3 SORT1 TMEM133
Primary Biliary Cirrhosis	3.48	3	1	2.2	0.00	1.0e+00	CISD2 FNDC4 SH2B3
Illnesses of father: None of the above (group 1)	3.48	2	0	0.0	0.00	1.0e+00	SH2B3 SLC22A3
Medication: Metformin	3.45	3	1	2.2	0.00	1.0e+00	CISD2 FNDC4 RP11-138A9.1
Taking other prescription medications	3.43	2	1	2.2	0.00	1.0e+00	CISD2 SH2B3
Diabetes (self-reported)	3.38	3	1	2.2	0.00	1.0e+00	CISD2 FNDC4 RP11-138A9.1
Heart disease (siblings)	3.38	2	0	0.0	0.00	1.0e+00	SLC22A3 SORT1
Breast Cancer	3.36	1	1	2.2	0.00	1.0e+00	TNNT3
Father's age at death	3.33	2	1	2.2	0.00	1.0e+00	SH2B3 SORT1
Coronary Artery Disease (CAD)	3.25	2	0	0.0	0.00	1.0e+00	SH2B3 SLC22A3
Pulse rate	3.19	1	1	2.2	0.00	1.0e+00	FNDC4
HDL Cholesterol	3.10	2	2	4.4	0.00	1.0e+00	RP11-138A9.1 SORT1
Leg fat-free mass (right)	3.03	6	1	2.2	0.88	2.2e-02	FNDC4 NUDT16L1 SH2B3 SLC22A3 SORT1 TMEM133
Leg fat-free mass (left)	3.02	6	1	2.2	0.87	2.4e-02	FNDC4 NUDT16L1 SH2B3 SLC22A3 SORT1 TMEM133
Leg predicted mass (left)	3.02	6	1	2.2	0.87	2.4e-02	FNDC4 NUDT16L1 SH2B3 SLC22A3 SORT1 TMEM133
Crohns Disease (2017)	3.01	2	2	4.4	0.00	1.0e+00	FNDC4 NTN5
Leg predicted mass (right)	3.01	6	1	2.2	0.88	2.2e-02	FNDC4 NUDT16L1 SH2B3 SLC22A3 SORT1 TMEM133
Medication for pain relief, constipation, heartburn	2.98	3	0	0.0	0.00	1.0e+00	CISD2 NUDT16L1 SORT1
Blood Red Count	2.96	7	3	6.7	-0.11	8.1e-01	FNDC4 MC1R MGRN1 NUDT16L1 RHOC RP11-138A9.1 SH2B3
Birth weight	2.94	3	1	2.2	0.00	1.0e+00	HOXA10 NTN5 SH2B3
Body Mass Index (BMI) (2010)	2.89	1	0	0.0	0.00	1.0e+00	NUDT16L1
Comparative body size at age 10	2.86	4	2	4.4	0.85	1.5e-01	ATG7 FNDC4 MC1R NTN5
Medication: Gliclazide	2.86	2	0	0.0	0.00	1.0e+00	CISD2 FNDC4
Type 2 Diabetes (T2D) (2012)	2.84	2	0	0.0	0.00	1.0e+00	CISD2 RP11-138A9.1
Comparative height size at age 10	2.84	7	3	6.7	0.80	3.2e-02	FNDC4 MC1R NTN5 NUDT16L1 SH2B3 SLC22A3 SORT1
Waist Hip Ratio (WHR)	2.79	5	3	6.7	-0.78	1.2e-01	NTN5 RP11-138A9.1 SLC22A3 TMEM133 TNNT3
Mouth/teeth dental problems: Dentures	2.75	2	1	2.2	0.00	1.0e+00	FNDC4 NTN5
Diabetes (father)	2.74	1	0	0.0	0.00	1.0e+00	FNDC4
Had menopause	2.68	1	0	0.0	0.00	1.0e+00	MC1R
Impedance of leg (left)	2.61	5	1	2.2	-0.35	5.6e-01	ATG7 FNDC4 MC1R RHOC TMEM133
Qualifications: O levels/GCSEs or equivalent	2.58	1	1	2.2	0.00	1.0e+00	NUDT16L1
Mean time to correctly identify matches	2.55	1	1	2.2	0.00	1.0e+00	SH2B3
Hip circumference	2.51	6	3	6.7	0.98	7.0e-04	FNDC4 NTN5 NUDT16L1 RP11-138A9.1 SH2B3 SLC22A3
Trunk fat percentage	2.47	6	3	6.7	0.77	7.5e-02	HOXA10 MC1R NUDT16L1 RP11-138A9.1 SLC22A3 STON1
Impedance of leg (right)	2.46	5	1	2.2	-0.41	4.9e-01	ATG7 FNDC4 MC1R RHOC TMEM133
Overall health rating	2.45	4	0	0.0	-0.99	1.0e-02	ATG7 CISD2 MGRN1 STON1
Weight	2.40	5	1	2.2	0.71	1.8e-01	FNDC4 NUDT16L1 SH2B3 SLC22A3 STON1
Alcohol drinker status: Previous	2.33	1	0	0.0	0.00	1.0e+00	RP11-138A9.1
Trunk fat mass	2.24	7	0	0.0	0.78	3.7e-02	FNDC4 HOXA10 MC1R NUDT16L1 RP11-138A9.1 SLC22A3 STON1
Number of children fathered	2.24	1	0	0.0	0.00	1.0e+00	NTN5
Forced expiratory volume in 1-second (FEV1), predicted	2.23	3	0	0.0	0.00	1.0e+00	MGRN1 NUDT16L1 RHOC
Fed-up feelings	2.17	2	1	2.2	0.00	1.0e+00	SH2B3 STON1
Hand grip strength (left)	2.16	5	0	0.0	0.68	2.0e-01	FNDC4 MGRN1 NUDT16L1 RHOC TNNT3
Body fat percentage	2.16	5	2	4.4	0.70	1.9e-01	HOXA10 MC1R RP11-138A9.1 SLC22A3 STON1
Irritable Bowel Disease (IBD)	2.14	3	1	2.2	0.00	1.0e+00	FNDC4 NTN5 SH2B3
Chest pain or discomfort	2.10	1	0	0.0	0.00	1.0e+00	NTN5
Standing height	2.07	8	7	15.6	0.97	5.0e-05	FNDC4 MGRN1 NTN5 NUDT16L1 RHOC SH2B3 SLC22A3 SORT1
Diabetes (mother)	2.06	1	0	0.0	0.00	1.0e+00	FNDC4
Pulse wave peak to peak time	2.06	1	0	0.0	0.00	1.0e+00	NUDT16L1
Headache pain in last month	2.05	1	0	0.0	0.00	1.0e+00	CISD2
Serious illness, injury or assault of a close relative in last 2 years	2.02	1	0	0.0	0.00	1.0e+00	NTN5
Loneliness, isolation	2.02	1	0	0.0	0.00	1.0e+00	SH2B3
Qualifications: nursing, teaching	2.01	2	0	0.0	0.00	1.0e+00	NUDT16L1 SH2B3
Mouth/teeth dental problems	2.00	2	0	0.0	0.00	1.0e+00	CISD2 NTN5
Reaction Time	1.99	1	1	2.2	0.00	1.0e+00	SH2B3
Supplements: Fish oil (including cod liver oil)	1.98	1	0	0.0	0.00	1.0e+00	SLC22A3
Lung FEV1/FVC ratio	1.97	4	2	4.4	0.61	3.9e-01	ATG7 NTN5 SORT1 TMEM133
Medication for hormone replacement therapy	1.97	1	0	0.0	0.00	1.0e+00	STON1
Whole body fat mass	1.97	7	0	0.0	0.76	4.7e-02	FNDC4 HOXA10 MC1R NUDT16L1 RP11-138A9.1 SLC22A3 STON1
Sitting height	1.94	6	1	2.2	0.75	8.7e-02	ATG7 FNDC4 NTN5 NUDT16L1 SLC22A3 TMEM133
Allergy or Eczema	1.92	3	0	0.0	0.00	1.0e+00	CISD2 FNDC4 SH2B3
Reason for reducing amount of alcohol drunk: Health precaution	1.91	1	0	0.0	0.00	1.0e+00	CISD2
Height	1.89	13	7	15.6	0.86	1.4e-04	ATG7 FNDC4 HOXA10 MC1R MGRN1 NTN5 NUDT16L1 RHOC SH2B3 SLC22A3 SORT1 TMEM133 TNNT3
Mother's age at death	1.88	1	0	0.0	0.00	1.0e+00	SH2B3
Hand grip strength (right)	1.86	3	0	0.0	0.00	1.0e+00	FNDC4 NUDT16L1 RHOC
Blood clot in the leg (DVT)	1.83	2	0	0.0	0.00	1.0e+00	MC1R SH2B3
Bipolar Disorder (2011)	1.82	1	0	0.0	0.00	1.0e+00	FNDC4
Average weekly spirits intake	1.81	1	0	0.0	0.00	1.0e+00	NTN5
Peak expiratory flow (PEF)	1.80	1	1	2.2	0.00	1.0e+00	NTN5
Forced vital capacity (FVC)	1.79	4	1	2.2	0.99	9.5e-03	CISD2 NUDT16L1 RHOC TMEM133
Forced expiratory volume in 1-second (FEV1)	1.79	3	0	0.0	0.00	1.0e+00	NUDT16L1 RHOC TMEM133
Long-standing illness, disability or infirmity	1.78	1	0	0.0	0.00	1.0e+00	SH2B3
Frequency of tiredness / lethargy in last 2 weeks	1.77	1	0	0.0	0.00	1.0e+00	SH2B3
Leg fat mass (right)	1.76	5	0	0.0	0.61	2.8e-01	FNDC4 HOXA10 RP11-138A9.1 SLC22A3 STON1
Leg fat mass (left)	1.76	5	0	0.0	0.60	2.8e-01	FNDC4 HOXA10 RP11-138A9.1 SLC22A3 STON1
Eye problems/disorders: Diabetes related eye disease	1.74	1	0	0.0	0.00	1.0e+00	MC1R
Osteoarthritis (self-reported)	1.73	1	0	0.0	0.00	1.0e+00	NUDT16L1
Schizophrenia vs Biploar Disorder	1.71	1	0	0.0	0.00	1.0e+00	FNDC4
Smoking status: Previous	1.71	1	0	0.0	0.00	1.0e+00	SH2B3
Age when periods started (menarche)	1.69	2	0	0.0	0.00	1.0e+00	NTN5 STON1
Arm fat mass (left)	1.69	6	0	0.0	0.75	8.3e-02	FNDC4 HOXA10 NUDT16L1 RP11-138A9.1 SLC22A3 STON1
Past tobacco smoking	1.68	1	0	0.0	0.00	1.0e+00	SH2B3
Chronotype (morning person)	1.66	1	0	0.0	0.00	1.0e+00	NTN5
Hayfever, allergic rhinitis or eczema	1.66	2	0	0.0	0.00	1.0e+00	FNDC4 SH2B3
Other serious medical condition/disability diagnosed by doctor	1.62	1	0	0.0	0.00	1.0e+00	SORT1
Migraine (self-reported)	1.62	1	0	0.0	0.00	1.0e+00	CISD2
Deep venous thrombosis (DVT) (self-reported)	1.62	2	0	0.0	0.00	1.0e+00	MC1R SH2B3
Arm fat mass (right)	1.61	6	0	0.0	0.77	7.2e-02	FNDC4 HOXA10 NUDT16L1 RP11-138A9.1 SLC22A3 STON1
Mineral and other dietary supplements	1.61	1	0	0.0	0.00	1.0e+00	SLC22A3
Depression (Nagel 2018)	1.60	1	0	0.0	0.00	1.0e+00	STON1
Medication: Lansoprazole	1.60	1	0	0.0	0.00	1.0e+00	SH2B3
Rheumatoid Arthritis	1.59	1	0	0.0	0.00	1.0e+00	SH2B3
Qualifications: None of the above	1.59	1	0	0.0	0.00	1.0e+00	NUDT16L1
Arm fat percentage (left)	1.59	6	1	2.2	0.75	8.4e-02	HOXA10 MC1R NUDT16L1 RP11-138A9.1 SLC22A3 STON1
Neck or shoulder pain in last month	1.58	1	0	0.0	0.00	1.0e+00	MC1R
Osteoporosis (self-reported)	1.58	1	0	0.0	0.00	1.0e+00	FNDC4
Average weekly fortified wine intake	1.57	1	0	0.0	0.00	1.0e+00	MC1R
Relative age voice broke	1.57	1	0	0.0	0.00	1.0e+00	MC1R
Arm fat percentage (right)	1.57	4	1	2.2	0.68	3.2e-01	HOXA10 RP11-138A9.1 SLC22A3 STON1
Prostate Cancer	1.56	1	0	0.0	0.00	1.0e+00	HOXA10
Heel bone mineral density (BMD) T-score, automated (left)	1.54	2	0	0.0	0.00	1.0e+00	CISD2 TMEM133
Depressed Affect (Nagel 2018)	1.53	2	0	0.0	0.00	1.0e+00	SH2B3 STON1
Leg fat percentage (right)	1.53	3	0	0.0	0.00	1.0e+00	HOXA10 RP11-138A9.1 STON1
Exposure to tobacco smoke outside home	1.53	1	0	0.0	0.00	1.0e+00	SH2B3
Basal cell carcinoma (self-reported)	1.53	1	0	0.0	0.00	1.0e+00	MC1R
Forced vital capacity (FVC), Best measure	1.52	2	0	0.0	0.00	1.0e+00	NUDT16L1 RHOC
Medication: Laxatives (e.g. Dulcolax, Senokot)	1.52	1	0	0.0	0.00	1.0e+00	FNDC4
Pain experienced in last month	1.52	1	0	0.0	0.00	1.0e+00	SH2B3
BMI	1.50	6	1	2.2	0.43	3.9e-01	ATG7 CISD2 FNDC4 RP11-138A9.1 SLC22A3 STON1
Leg fat percentage (left)	1.49	4	0	0.0	0.48	5.2e-01	HOXA10 MC1R RP11-138A9.1 STON1
Forced expiratory volume in 1-second (FEV1), Best measure	1.48	3	0	0.0	0.00	1.0e+00	NUDT16L1 RHOC TMEM133
Mouth/teeth dental problems: Mouth ulcers	1.47	1	0	0.0	0.00	1.0e+00	SH2B3
Medication: Ibuprofen	1.46	1	0	0.0	0.00	1.0e+00	SLC22A3
Hair/balding pattern: Pattern 4	1.44	2	0	0.0	0.00	1.0e+00	ATG7 NUDT16L1
Lung FVC	1.43	5	0	0.0	-0.24	7.0e-01	CISD2 FNDC4 HOXA10 SH2B3 STON1
Average weekly red wine intake	1.43	1	0	0.0	0.00	1.0e+00	SLC22A3
Heel bone mineral density (BMD) T-score, automated (right)	1.42	2	0	0.0	0.00	1.0e+00	ATG7 TMEM133
Ulcerative Colitis (UC)	1.41	1	0	0.0	0.00	1.0e+00	CISD2
Lupus	1.41	2	0	0.0	0.00	1.0e+00	NTN5 SH2B3
Ever smoked	1.41	1	0	0.0	0.00	1.0e+00	SH2B3
Illnesses of siblings: Diabetes	1.39	1	0	0.0	0.00	1.0e+00	FNDC4
Bipolar Disorder (2018)	1.38	1	0	0.0	0.00	1.0e+00	FNDC4
Myopia	1.37	1	0	0.0	0.00	1.0e+00	RHOC
Number of live births	1.36	1	0	0.0	0.00	1.0e+00	CISD2
Illness, injury, bereavement, stress in last 2 years	1.35	1	0	0.0	0.00	1.0e+00	MC1R
Schizophrenia (2014)	1.34	1	0	0.0	0.00	1.0e+00	CISD2
Allergy	1.34	1	0	0.0	0.00	1.0e+00	CISD2
Mood swings	1.34	1	0	0.0	0.00	1.0e+00	SH2B3
Bipolar Disorder or Schizophrenia	1.32	3	0	0.0	0.00	1.0e+00	CISD2 NTN5 RHOC
Neuroticism (Nagel 2018)	1.28	2	0	0.0	0.00	1.0e+00	ATG7 CISD2
Time employed in main current job	1.27	1	0	0.0	0.00	1.0e+00	MC1R
Medication: Ibuprofen (e.g. Nurofen)	1.26	1	0	0.0	0.00	1.0e+00	SLC22A3
Seen doctor (GP) for nerves, anxiety, tension or depression	1.26	1	0	0.0	0.00	1.0e+00	MC1R
Crohns Disease (2012)	1.22	1	0	0.0	0.00	1.0e+00	FNDC4
Neuroticism	1.22	1	0	0.0	0.00	1.0e+00	ATG7
Frequency of unenthusiasm / disinterest in last 2 weeks	1.19	1	0	0.0	0.00	1.0e+00	SH2B3
Qualifications: A levels/AS levels or equivalent	1.17	1	0	0.0	0.00	1.0e+00	NUDT16L1
Heel T-Score	1.14	5	2	4.4	0.39	5.2e-01	ATG7 HOXA10 RHOC SORT1 TMEM133
Schizophrenia (2018)	1.13	2	0	0.0	0.00	1.0e+00	CISD2 RHOC
Forced expiratory volume in 1-second (FEV1), predicted percentage	1.13	1	0	0.0	0.00	1.0e+00	TMEM133
Back pain experienced in last month	1.12	1	0	0.0	0.00	1.0e+00	SH2B3
Smoking Status	1.06	1	0	0.0	0.00	1.0e+00	SORT1
Body mass index (BMI)	1.06	1	0	0.0	0.00	1.0e+00	FNDC4
Sensitivity / hurt feelings	1.05	1	0	0.0	0.00	1.0e+00	CISD2
Waist circumference	1.05	2	0	0.0	0.00	1.0e+00	FNDC4 NUDT16L1
Worry (Nagel 2018)	0.86	1	0	0.0	0.00	1.0e+00	ATG7

Associations by panel

study	tissue	# hits	% hits/tests	avg chisq
GTEx	Small Intestine Terminal Ileum	0	0.000	1.7
GTEx	Adipose Visceral Omentum	1	0.049	1.6
GTEx	Artery Aorta	0	0.000	1.6
GTEx	Brain Frontal Cortex BA9	0	0.000	1.6
GTEx	Brain Nucleus accumbens basal ganglia	0	0.000	1.6
GTEx	Breast Mammary Tissue	0	0.000	1.6
GTEx	Breast Mammary Tissue (Male)	0	0.000	1.6
GTEx	Breast Mammary Tissue (Female)	0	0.000	1.6
GTEx	Cells EBV-transformed lymphocytes	0	0.000	1.6
GTEx	Cells Transformed fibroblasts	0	0.000	1.6
GTEx	Colon Sigmoid	0	0.000	1.6
GTEx	Heart Atrial Appendage	0	0.000	1.6
GTEx	Lung	0	0.000	1.6
GTEx	Ovary	0	0.000	1.6
GTEx	Pancreas	0	0.000	1.6
GTEx	Prostate	0	0.000	1.6
GTEx	Skin Not Sun Exposed Suprapubic	1	0.041	1.6
GTEx	Spleen	0	0.000	1.6
GTEx	Stomach	0	0.000	1.6
GTEx	Thyroid	0	0.000	1.6
GTEx	Uterus	0	0.000	1.6
GTEx	Whole Blood	1	0.050	1.6
ROSMAP	Brain Pre-frontal Cortex	0	0.000	1.6
The Cancer Genome Atlas	Colon Adenocarcinoma	0	0.000	1.6
The Cancer Genome Atlas	Head and Neck Squamous Cell Carcinoma	0	0.000	1.6
The Cancer Genome Atlas	Kidney Renal Papillary Cell Carcinoma	2	0.098	1.6
The Cancer Genome Atlas	Ovarian Serous Cystadenocarcinoma	1	0.063	1.6
The Cancer Genome Atlas	Rectum Adenocarcinoma	0	0.000	1.6
GTEx	Adipose Subcutaneous	0	0.000	1.5
GTEx	Adrenal Gland	0	0.000	1.5
GTEx	Artery Coronary	0	0.000	1.5
GTEx	Artery Tibial	2	0.053	1.5
GTEx	Brain Cerebellar Hemisphere	0	0.000	1.5
GTEx	Brain Cerebellum	0	0.000	1.5
GTEx	Brain Cortex	0	0.000	1.5
GTEx	Brain Hypothalamus	0	0.000	1.5
GTEx	Colon Transverse	0	0.000	1.5
GTEx	Esophagus Gastroesophageal Junction	0	0.000	1.5
GTEx	Esophagus Mucosa	0	0.000	1.5
GTEx	Esophagus Muscularis	1	0.031	1.5
GTEx	Heart Left Ventricle	1	0.065	1.5
GTEx	Liver	0	0.000	1.5
GTEx	Muscle Skeletal	2	0.069	1.5
GTEx	Nerve Tibial	0	0.000	1.5
GTEx	Pituitary	0	0.000	1.5
GTEx	Skin Sun Exposed Lower leg	0	0.000	1.5
GTEx	Testis	0	0.000	1.5
GTEx	Vagina	0	0.000	1.5
METSIM	Adipose	2	0.043	1.5
NTR	Blood	0	0.000	1.5
CommonMind	Brain Pre-frontal Cortex	2	0.037	1.5
The Cancer Genome Atlas	Breast Invasive Carcinoma	1	0.023	1.5
The Cancer Genome Atlas	Cervical Squamous Cell Carcinoma	0	0.000	1.5
The Cancer Genome Atlas	Esophageal Carcinoma	0	0.000	1.5
The Cancer Genome Atlas	Glioblastoma Multiforme	0	0.000	1.5
The Cancer Genome Atlas	Kidney Renal Clear Cell Carcinoma	0	0.000	1.5
The Cancer Genome Atlas	Brain Lower Grade Glioma	0	0.000	1.5
The Cancer Genome Atlas	Liver Hepatocellular Carcinoma	1	0.090	1.5
The Cancer Genome Atlas	Lung Adenocarcinoma	0	0.000	1.5
The Cancer Genome Atlas	Lung Squamous Cell Carcinoma	0	0.000	1.5
The Cancer Genome Atlas	Pancreatic Adenocarcinoma	0	0.000	1.5
The Cancer Genome Atlas	Pheochromocytoma and Paraganglioma	0	0.000	1.5
The Cancer Genome Atlas	Soft Tissue Sarcoma	0	0.000	1.5
The Cancer Genome Atlas	Skin Cutaneous Melanoma	0	0.000	1.5
The Cancer Genome Atlas	Stomach Adenocarcinoma	0	0.000	1.5
The Cancer Genome Atlas	Thyroid Carcinoma	3	0.058	1.5
GTEx	Brain Caudate basal ganglia	0	0.000	1.4
GTEx	Brain Hippocampus	0	0.000	1.4
GTEx	Brain Putamen basal ganglia	0	0.000	1.4
YFS	Blood	2	0.043	1.4
The Cancer Genome Atlas	Bladder Urothelial Carcinoma	0	0.000	1.4
The Cancer Genome Atlas	Prostate Adenocarcinoma	0	0.000	1.4
The Cancer Genome Atlas	Testicular Germ Cell Tumors	0	0.000	1.4
The Cancer Genome Atlas	Uterine Corpus Endometrial Carcinoma	0	0.000	1.4